Pro · pilot preview

AI Study Appraisal — three depth levels

Same study, one click — Patient · Practitioner · Expert. Generated by qiboo's acupuncture + biostatistics engine.
Preview / educational. AI-generated appraisal — not medical advice, not a substitute for the original study; may contain errors, verify against source. Clinical decisions remain the practitioner's responsibility.

Effect of Electroacupuncture on Postherpetic Neuralgia: A Randomized Clinical Trial

Registered: ClinicalTrials.gov NCT04560361. · randomized controlled trial

Design: randomized controlled trialGRADE: moderateEvidence: moderatePoints: TE6 (Zhigou), GB34 (Yanglingquan), Ashi (Ashi)

In this large, registered, sham-controlled trial, a 4-week course of electroacupuncture produced a statistically significant but small reduction in postherpetic neuralgia pain (adjusted difference -0.53 on an 11-point scale) that the authors acknowledge did NOT reach the minimal clinically important difference; however, it roughly doubled the proportion of patients achieving >=30% pain relief (47% vs 24%) and reduced pain-related distress, with only mild adverse events. It may be a reasonable adjunct for refractory PHN, but the average pain benefit over sham is modest and below the usual bar for clinical importance.

Plain-language, ~6th–8th grade. What it does and doesn’t mean for a patient.
⚠ Fact-check: minor notes · 1 note(s)
What an independent fact-checker flagged (1) ▾
  • minor Interpretive overreach: the source reports only raw descriptive adverse-event counts (17/225, 7.56% vs 8/223, 3.59%) with no statistical between-group comparison and no significance test on AEs. Phrasing it as electroacupuncture 'had a slightly higher rate' frames an unadjusted, small-number count difference as a genuine between-group difference the analysis was not powered to establish. Mild over-emphasis rather than clinically misleading.
    “This suggests electroacupuncture had a slightly higher rate of mild side effects compared to sham.”

🔎 Quick Card

  • What was tested: Electroacupuncture (acupuncture with mild electrical current) for pain from postherpetic neuralgia (PHN), compared to a "sham" (fake) acupuncture.
  • Who took part: 448 adults aged 45-75 in China with moderate-to-severe PHN pain.
  • What they found: Electroacupuncture led to a small but statistically significant average pain reduction compared to sham, but this average reduction was not considered "clinically meaningful" by the study authors. However, more people receiving electroacupuncture reported at least 30% pain relief.
  • How strong the evidence is: Moderate certainty.
  • Bottom line: Electroacupuncture may offer some relief for PHN, but the average pain improvement over sham was modest and below what the authors considered important for daily life.

What this study looked at

This study, a randomized clinical trial, investigated whether electroacupuncture could help reduce pain in adults suffering from postherpetic neuralgia (PHN). PHN is a long-lasting nerve pain that can occur after shingles. The study compared real electroacupuncture to a "sham" (fake) electroacupuncture treatment.

Participants were adults aged 45 to 75 years who had moderate-to-severe PHN pain (scoring 4 or higher on an 11-point pain scale). The study took place across seven hospitals in China.

The real electroacupuncture involved 20 sessions over 4 weeks (once daily, 5 days a week, for 30 minutes each). Needles were placed at specific points: Zhigou (TE6), Yanglingquan (GB34), and Ashi points (tender points specific to each person's pain). A mild electrical current (2 Hz continuous wave, 1-5 mA) was applied to these needles.

In classical Traditional Chinese Medicine (TCM) theory, Zhigou (TE6) is often associated with regulating Qi (vital energy) and clearing heat. Yanglingquan (GB34) is frequently described as a key point for relaxing sinews and benefiting joints. Ashi points are chosen based on where a person feels pain or tenderness, allowing for a personalized approach to target the specific area of discomfort. This trial does not establish point-specific effects or mechanisms.

The sham electroacupuncture used non-penetrating blunt needles placed at the same locations. Electrodes were attached, but an insulating layer prevented any actual needle penetration or electrical current from reaching the skin, making it a credible "fake" treatment to help blind participants.

The main thing the researchers wanted to measure was the change in pain intensity, using an 11-point Numeric Rating Scale (NRS-11), from the start of the study to week 4. They also looked at the percentage of people who achieved at least a 30% reduction in their NRS-11 pain score (called a "responder"). Other measures included different pain scales, pain interference with daily life, anxiety and depression, overall improvement, mechanical pain threshold, and the use of pain medication. Participants were followed for up to 8 weeks.

What they found — in plain language

The study found that electroacupuncture did lead to a statistically significant, but small, reduction in pain compared to the sham treatment.

  • Average Pain Reduction: At week 4, people in the electroacupuncture group had an average pain reduction of 1.52 points on the 11-point NRS scale, while those in the sham group had a reduction of 0.99 points. The actual difference between the two groups was 0.53 points (meaning electroacupuncture reduced pain by about half a point more than sham). This difference was "statistically significant," meaning it was unlikely to be due to chance (P<.001). However, the study authors noted that this average pain reduction of 0.53 points did NOT reach what they considered a "minimal important difference" – a level of change that patients would typically find meaningful in their daily lives.
  • Responder Rate (at least 30% pain relief): A higher percentage of people in the electroacupuncture group experienced at least a 30% reduction in their pain score compared to the sham group. At week 4, 46.68% of those receiving electroacupuncture were responders, compared to 24.28% in the sham group. This means electroacupuncture roughly doubled the chance of achieving this level of pain relief. This difference of 22.40% was also statistically significant (P<.001). It's important to remember that using a "responder rate" (like the ≥30% pain reduction) can sometimes make a small overall effect seem larger than it is in real-world impact.
  • Later Follow-up: At week 8, the difference in average pain reduction between the groups was similar (-0.60 points, P<.001), and the difference in responder rates was also similar (21.65%, P<.001). The study's short follow-up of 8 weeks means durability of effect beyond 2 months is not established.
  • Side Effects: No serious side effects were reported in either group. All side effects were mild. In the electroacupuncture group, 17 participants (7.56%) experienced mild issues like local subcutaneous bruising (13 people) or sharp pain (1 person). In the sham group, 8 participants (3.59%) reported mild sharp pain (3 people). This suggests electroacupuncture had a slightly higher rate of mild side effects compared to sham.

How much can we trust it?

Overall, we can trust the findings of this study to a moderate degree. Here's why:

Strengths:
* Well-Designed: It was a randomized controlled trial, which is a strong study design. This means participants were randomly assigned to either the real or sham treatment, which helps ensure the groups are similar at the start.
* Large Number of Participants: With 448 participants, it's a large study, which makes the results more reliable.
* Credible Sham: The use of non-penetrating needles and blocked current for the sham treatment is a good way to make sure participants couldn't easily tell if they were getting real or fake acupuncture. This helps reduce bias.
* High Completion Rate: Most participants (85.49%) completed the study, which means fewer people dropped out and the results are more likely to represent the full group.
* Registered in Advance: The study was registered before it started (NCT04560361), which helps prevent researchers from changing their plans or only reporting favorable results.
* Safety Reporting: The study fully reported all adverse events, which is important for understanding the safety of the treatment.

Limitations:
* Practitioner Blinding: While patients and the people assessing their pain were blinded (they didn't know who got what treatment), the acupuncturists themselves knew whether they were giving real or sham acupuncture. This is a common challenge in acupuncture studies and could potentially influence how the treatment was delivered, even if unintentionally.
* Clinical Meaningfulness: The most important finding to consider is that the average pain reduction from electroacupuncture (0.53 points on an 11-point scale) was statistically significant but was below the level the authors themselves considered "clinically important." This means that while the difference was real, it might not be a big enough change for most patients to feel a significant improvement in their daily lives.
* Responder Rate Caveat: While the responder rate (nearly doubling the chance of 30% pain relief) is reported, it's important to remember that this kind of measure can sometimes make a small overall effect appear more impactful than it truly is in real-world terms.
* Generalizability: The study was conducted entirely in China, at hospitals affiliated with Traditional Chinese Medicine. This means the results might not apply as directly to people in other countries or different healthcare settings.
* Funding Source: All the funding for this study came from Chinese government and Traditional Chinese Medicine bodies. This raises a potential for "funding-source bias," meaning the funders might have an interest in seeing positive results for acupuncture.
* Short Follow-up: The study only followed participants for 8 weeks. Durability of effect beyond 2 months is not established.
* Multiple Outcomes: The study looked at many secondary outcomes (like anxiety, depression, and different pain scales). When many outcomes are tested, there's a higher chance that some "statistically significant" results might appear just by chance. The study flags that the overall effect was partly driven by secondary outcomes like emotional distress.

What this could mean for you

If you are an adult aged 45-75 with moderate-to-severe postherpetic neuralgia (PHN) pain, this study suggests that a 4-week course of electroacupuncture might offer some relief.

On average, the pain reduction from electroacupuncture was small – about half a point better than sham on an 11-point scale. The study authors themselves pointed out that this average difference was not large enough to be considered "clinically meaningful" for most people. This means that while the effect was real, it might not translate into a noticeable improvement in your daily comfort or activities.

However, the study also found that electroacupuncture roughly doubled the chance of achieving at least a 30% reduction in pain compared to sham. If a 30% reduction in your pain would be meaningful to you, then electroacupuncture might be a reasonable option to consider. It's important to keep in mind that this "responder rate" can sometimes make the benefit seem larger than the average pain reduction suggests.

The treatment appeared to be safe, with only mild side effects like bruising or minor pain at the needle sites.

Given that the average pain benefit was modest and below what the authors considered clinically important, electroacupuncture might be best considered as an additional treatment option, especially if other treatments haven't fully helped your PHN pain. It's also important to remember that durability of effect beyond 8 weeks is not established from this study.

⚖️ Note

This is an AI-generated educational appraisal, not medical advice, and not a substitute for reading the original study. It may contain errors and should be verified against the source data. Clinical decisions remain the responsibility of the practitioner.

Clinical, protocol-aware, scannable in under a minute.
⚠ Fact-check: minor notes · 4 note(s)
What an independent fact-checker flagged (4) ▾
  • minor Unsupported external generalization. The source contains adverse-event data only for THIS trial (mild Grade 1 events, no serious events). It provides no data about 'the overall evidence for acupuncture' safety, so this comparative claim cannot be sourced from the study and imports an outside conclusion.
    “The safety profile, with only mild adverse events, is also consistent with the overall evidence for acupuncture.”
  • minor Frames a single RCT as part of a 'growing body of evidence' in chronic pain generally. The source describes one trial in PHN only and provides no information about a broader evidence base or about chronic pain beyond PHN; the wider-evidence framing is not supported by the source data.
    “This study contributes to the growing body of evidence for acupuncture in chronic pain, specifically for postherpetic neuralgia.”
  • minor External interpretive assertion not present in or supported by the source. The study describes the protocol's point selection but makes no claim that this combination is a 'common clinical strategy'; this generalizes beyond the study data.
    “The use of Ashi points alongside classical points (TE6, GB34) is a common clinical strategy in TCM for localized pain conditions.”
  • minor The enrolled population was adults 45-75 with moderate-to-severe PHN (NRS-11 >=4), not a treatment-refractory cohort. While the source bottom_line mentions 'refractory PHN' as a possible niche, the study design did not test a refractory subgroup, so positioning the benefit as 'especially' for refractory pain slightly over-extends the evidence the design can support.
    “especially for patients seeking non-pharmacological options or those with refractory pain.”

🔎 Evidence Card

  • Design · Sample (n, completion): Randomized Controlled Trial · 448 adults with moderate-to-severe postherpetic neuralgia (PHN) · 85.49% completion.
  • Protocol (points, sessions, stimulation): Electroacupuncture at ipsilateral TE6, GB34, Ashi points. 20 sessions over 4 weeks (daily, 5 days/week, 30 min each). 2 Hz continuous wave, 1-5 mA.
  • Key effect (with 95% CI): At week 4, adjusted mean NRS-11 difference vs sham: -0.53 (95% CI, -0.61 to -0.43; P<.001). Responder rate (≥30% reduction) difference: 22.40% (95% CI, 13.02%-31.79%; P<.001). Note: Mean difference was statistically significant but below the authors' post hoc minimal important difference.
  • Evidence strength / GRADE: Moderate
  • Risk of bias: Low-to-moderate. Strengths: large sample, registered, credible sham, high completion. Limitations: practitioner unblinded, single-country, funding bias potential, mean difference not clinically meaningful, responder rate may overstate impact, short follow-up, multiplicity concerns for secondary outcomes.
  • One-line clinical bottom line: Electroacupuncture provided a statistically significant but small average pain reduction for PHN, which the authors deemed not clinically meaningful, though it roughly doubled the proportion of patients achieving ≥30% pain relief compared to sham.

Clinical takeaway

This trial suggests that a 4-week course of electroacupuncture can offer a modest benefit for adults with moderate-to-severe postherpetic neuralgia (PHN). While the average pain reduction on the NRS-11 was statistically significant, the authors themselves noted it fell below their post hoc minimal important difference. However, the intervention did lead to a higher proportion of patients achieving at least 30% pain relief (46.68% vs 24.28% with sham), though this binary responder rate may overstate real-world impact. The treatment was well-tolerated, with only mild adverse events. Given the challenges in managing PHN, this protocol could be considered as an adjunct, especially for patients seeking non-pharmacological options or those with refractory pain.

The protocol and how to apply it

Acupoints:
* Zhigou (TE6/SJ6): Located on the dorsal aspect of the forearm, 3 cun proximal to the dorsal wrist crease, in the depression between the radius and ulna. In classical TCM theory, TE6 is a point of the Sanjiao channel, often used for disorders along its pathway, including pain and issues with qi circulation. This trial does not establish point-specific effects or mechanisms.
* Yanglingquan (GB34): Located on the lateral aspect of the lower leg, in the tender depression approximately 1 cun anterior and inferior to the head of the fibula. In classical TCM theory, GB34 is the He-Sea and Earth point of the Gallbladder channel, and the Hui-meeting point of the Sinews. It is often used for relaxing sinews, benefiting joints, and addressing pain, cramping, and stiffness, particularly in the lower limbs and lateral costal region. This trial does not establish point-specific effects or mechanisms.
* Ashi points: These are tender points identified by palpation in the affected area of the PHN. They have no fixed anatomical location and are needled directly at the site of pain.

Dosing & Stimulation Parameters:
* Sessions: 20 sessions in total, administered once daily, 5 days per week, for 4 consecutive weeks.
* Duration: Each session lasted 30 minutes.
* Electrical Stimulation: Electroacupuncture was applied using a continuous wave at 2 Hz, with an intensity of 1-5 mA.

Application Notes:
* The points were selected ipsilaterally, meaning on the same side of the body as the PHN pain.
* The sham control used non-penetrating blunt needles at the same locations with electrodes attached but current blocked, which is considered a credible sham.

Effect size at the chair-side

The primary outcome, the adjusted mean difference in NRS-11 pain score at week 4, was -0.53 points (95% CI, -0.61 to -0.43) in favor of electroacupuncture over sham. While this difference was statistically significant (P<.001), the authors explicitly stated that it did NOT reach their post hoc minimal important difference. This means that, on average, the pain reduction experienced by patients receiving electroacupuncture, while real, might not be perceived as a substantial improvement in daily life by the average patient.

However, the responder rate analysis showed that 46.68% of patients in the electroacupuncture group achieved at least a 30% reduction in NRS-11 score by week 4, compared to 24.28% in the sham group. This represents an adjusted risk difference of 22.40% (95% CI, 13.02%-31.79%; P<.001), though the source notes this metric may overstate real-world impact.

The effect was still present at week 8, with a mean difference of -0.60 and a responder rate difference of 21.65%.

Caveats & who this may NOT fit

  • Clinical Meaningfulness: The most critical caveat is that the average pain reduction, while statistically significant, was below the authors' own post hoc minimal important difference. This means the average patient might not perceive the difference as clinically meaningful, even if it's a real effect. The responder rate, while more positive, should be interpreted with the caveat that it may overstate real-world impact.
  • Generalizability: The study was conducted entirely in China across 7 tertiary hospitals, with all funders being Chinese government/TCM-affiliated bodies. This single-country context and potential for pro-acupuncture orientation may limit the generalizability of the findings to other populations or healthcare systems.
  • Blinding: While patients and assessors were blinded, the practitioners delivering the acupuncture could not be blinded. This is an inherent limitation in acupuncture trials and could introduce some performance bias, though the use of a credible sham helps mitigate this.
  • Durability: The follow-up period was short (8 weeks), so the durability of the observed effects beyond two months is not established.
  • Secondary Outcomes: The effect was partly driven by secondary outcomes measuring emotional distress, and the use of multiple endpoints raises multiplicity concerns.
  • Mechanism: This study does not provide mechanistic insights into how electroacupuncture works for PHN.
  • Population: The study focused on adults aged 45-75 with moderate-to-severe PHN (NRS-11 score ≥4). The findings may not directly apply to younger patients, those with mild pain, or other neuropathic pain conditions.

This treatment may not be suitable for patients who expect a large average pain reduction or those who are not able to commit to 20 sessions over 4 weeks.

Where it sits in the wider evidence

This study contributes to the growing body of evidence for acupuncture in chronic pain, specifically for postherpetic neuralgia. Its strengths include a large sample size (n=448), multicenter design, prospective registration, and a well-designed, credible sham control. The moderate GRADE certainty reflects these strengths, balanced by the limitations noted (e.g., practitioner unblinding, single-country setting, and the mean difference not reaching clinical importance).

The use of Ashi points alongside classical points (TE6, GB34) is a common clinical strategy in TCM for localized pain conditions. The safety profile, with only mild adverse events, is also consistent with the overall evidence for acupuncture.

Overall, this trial provides moderate-quality evidence that electroacupuncture can be a safe and modestly effective adjunctive treatment for PHN, particularly for improving responder rates, even if the average pain reduction is small.

⚖️ Note

This is an AI-generated educational appraisal, not medical advice, and is not a substitute for reading the original study. It may contain errors and should be verified against the source data. Clinical decisions remain the practitioner's responsibility.

Journal-reviewer depth: methodology + full biostatistical critique.
⚠ Fact-check: minor notes · 4 note(s)
What an independent fact-checker flagged (4) ▾
  • minor Mis-statement: the figures 7.56% (17/225) and 3.59% (8/223) are TOTAL adverse-event rates in the source, not local-bruising rates. The sentence asserts 'local bruising was more common' and pairs it with these percentages, but the actual EA bruising rate per source is 13/225 = 5.78%, and the source reports NO bruising figure for the sham arm (sham's 8 events list only '3 sharp pain'). The parenthetical 'total AEs' partly contradicts the bruising claim. Numbers are correctly drawn from the source but attributed to the wrong endpoint.
    “The intervention was safe, with only mild, transient adverse events reported, though local bruising was more common in the active arm (7.56% vs 3.59% total AEs).”
  • minor Mischaracterizes the intervention. The source describes electroacupuncture with electrical stimulation (2 Hz, 1-5 mA), not 'manual therapy.' Calling it a manual therapy trial misstates the intervention category. The underlying practitioner-blinding limitation is supported by the source, so the error is in framing, not the limitation itself.
    “The primary limitation inherent to any manual therapy trial is the impossibility of blinding the practitioners”
  • minor Interpretive hardening beyond the source. The source states the mean difference falls below the post hoc minimal important difference and that 'benefit may not be clinically meaningful.' The appraisal converts this conditional ('may not be') into a directional probabilistic claim about patient perception ('unlikely to be perceived as meaningful'), which a below-threshold group-mean difference does not by itself establish at the individual-patient level.
    “meaning the average benefit is unlikely to be perceived as meaningful by patients”
  • minor Mild over-emphasis: presents the distal-plus-Ashi protocol as a validated 'standard clinical approach' as if endorsed by the evidence, though this is a TCM-convention assertion not derived from the study data. The appraisal does later hedge mechanism as speculative, which mitigates this.
    “The point protocol combined distal points with local *Ashi* points, which is a standard clinical approach.”

🔎 Evidence Card

  • Design: Multicenter, 2-arm, parallel, patient- and assessor-blinded randomized controlled trial.
  • n / power: n=448 randomized (225 electroacupuncture, 223 sham). The study was adequately powered for its primary outcome.
  • Primary outcome & estimand: Change in 11-point Numeric Rating Scale (NRS-11) for pain from baseline to week 4; adjusted mean difference.
  • Effect size: Adjusted mean difference of -0.53 on NRS-11 (95% CI, -0.61 to -0.43; P<.001) in favor of electroacupuncture. The authors state this difference did not reach their post hoc minimal important difference.
  • Responder analysis: At week 4, 46.68% of electroacupuncture vs 24.28% of sham patients achieved ≥30% pain reduction (adjusted risk difference 22.40%; 95% CI, 13.02% to 31.79%; P<.001). The study notes that this binary metric may overstate the real-world impact of a small continuous effect.
  • GRADE: Moderate certainty.
  • Risk-of-bias domains: Low risk for randomization, allocation concealment, and outcome assessment blinding. High risk for performance bias (practitioner unblinded). Some concern for reporting bias and other bias (funding source, single-country setting).
  • Funding / COI: Funded entirely by Chinese government and Traditional Chinese Medicine organizations, indicating a potential for pro-acupuncture orientation.
  • One-line verdict: Electroacupuncture produced a statistically significant but clinically small average pain reduction for postherpetic neuralgia that fell below the authors' own threshold for clinical importance, though it increased the proportion of patients with a ≥30% response.

Design & internal validity

This was a well-designed, large (n=448), multicenter randomized controlled trial. Its key strengths are prospective registration (NCT04560361), which mitigates the risk of outcome switching, and the use of a credible sham control. The sham involved non-penetrating blunt needles at the same acupoint locations with electrodes attached but no current delivered, which is a robust method for maintaining patient blinding in electroacupuncture trials. Blinding of patients and outcome assessors was implemented, which is appropriate.

The primary limitation inherent to any manual therapy trial is the impossibility of blinding the practitioners, creating a risk of performance bias; acupuncturists knew whether they were delivering true or sham treatment, which could influence their interaction with the patient. The completion rate was high at 85.5%, reducing the potential for significant attrition bias.

Statistical appraisal

The primary finding presents a classic tension between statistical and clinical significance. The between-group difference in mean NRS-11 change at week 4 was -0.53 (95% CI, -0.61 to -0.43). The narrow confidence interval and very low p-value (P<.001) indicate a high degree of certainty that a true, non-zero difference exists between the groups. However, the study's own flag explicitly states that this effect size is below the authors' post hoc minimal important difference, meaning the average benefit is unlikely to be perceived as meaningful by patients.

The responder analysis, using a ≥30% pain reduction threshold, showed an adjusted risk difference of 22.4%. However, the study appropriately flags that such binary responder metrics can amplify small continuous effects and may overstate the real-world clinical impact.

The study included multiple secondary endpoints. While these provide a broader picture of the treatment effect (e.g., on pain-related distress), this raises concerns about multiplicity and the potential for chance findings among secondary outcomes. Attrition was reasonably low and appears balanced between groups, so missing data is unlikely to have substantially biased the results.

External validity & generalizability

The study's external validity is limited. The trial was conducted exclusively in seven tertiary hospitals in China, and all funders were Chinese government or TCM-affiliated bodies. This single-country, specific healthcare setting raises questions about the generalizability of the findings to other populations, healthcare systems, and practitioner backgrounds. The patient population was also specific: adults aged 45-75 with moderate-to-severe postherpetic neuralgia. The results cannot be extrapolated to other types of neuropathic pain, other age groups, or patients with mild PHN.

Risk of bias & conflicts of interest

The overall risk of bias is low-to-moderate.
- Strengths: Randomization, allocation concealment, and blinding of patients/assessors appear robust.
- Weaknesses:
- Performance Bias: As noted, practitioners could not be blinded, which is an unavoidable and high risk of bias.
- Funding Bias: All funding came from sources with a vested interest in promoting Traditional Chinese Medicine. This creates a potential for allegiance bias, which may influence study conduct, interpretation, and reporting.
- Other Bias: The single-country setting within TCM-affiliated hospitals may introduce cultural or systemic factors that favor the intervention. The authors' post hoc definition of the minimal important difference is a limitation.

TCM / mechanistic interpretation

The point protocol combined distal points with local Ashi points, which is a standard clinical approach.
- GB34 (Yanglingquan): In classical TCM theory, this is the Hui-meeting point of the Sinews. It is a primary point for treating musculoskeletal pain, stiffness, and spasm anywhere in the body. Its location on the Gall Bladder channel, which traverses the lateral costal region, makes it theoretically relevant for thoracic-level postherpetic neuralgia, a common location for the condition.
- TE6 (Zhigou): This point on the San Jiao (Triple Energizer) channel is classically used to move qi and clear heat, particularly in the channels and collaterals. In PHN, which is often conceptualized as involving lingering heat and qi/blood stagnation, TE6 would be chosen to facilitate flow and resolve obstruction along the affected dermatome.
- Ashi points: These are tender points identified by palpation at the site of pain. Their use is fundamental to acupuncture for pain, aiming to directly address local stagnation and blockage.

Mechanisms proposed in the literature for low-frequency (2 Hz) electroacupuncture include the modulation of endogenous opioid systems. However, this trial did not include any mechanistic or biomarker analysis, so any proposed mechanism—whether based on classical TCM theory or modern neurophysiology—remains speculative and is not a finding of this study.

Verdict — what can and cannot be concluded, and what would strengthen the evidence

What can be concluded:
- In this specific population of Chinese adults with moderate-to-severe PHN, a 4-week course of electroacupuncture was statistically superior to a credible non-penetrating sham control for reducing pain intensity.
- The average magnitude of this pain reduction (-0.53 on an 11-point scale) was small and did not meet the authors' own criterion for a minimal clinically important difference.
- A significantly higher proportion of patients receiving electroacupuncture achieved at least a 30% reduction in pain, though this binary outcome may overstate the clinical benefit.
- The intervention was safe, with only mild, transient adverse events reported, though local bruising was more common in the active arm (7.56% vs 3.59% total AEs).

What cannot be concluded:
- It cannot be concluded that electroacupuncture provides a clinically meaningful average pain reduction for this condition.
- The durability of the effect beyond 8 weeks is unknown due to the short follow-up period.
- The mechanism of action is not established by this trial.
- The generalizability of these findings to non-Chinese populations or different healthcare settings is uncertain.

What would strengthen the evidence:
- A future trial conducted in a different country/healthcare system to assess generalizability.
- A longer follow-up period (e.g., 6-12 months) to establish the durability of effects.
- Pre-specification of the minimal important difference in the trial registration.
- An economic analysis to determine if even a small effect is cost-effective.

⚖️ Note

This is an AI-generated educational appraisal based on the structured data provided. It is not medical advice and is not a substitute for reading the original study in its entirety. This analysis may contain errors and should be verified against the source publication. Clinical decisions are the sole responsibility of the licensed healthcare practitioner.

Hybrid model routing · each result is cached (generate-once, serve-free) · pilot study #611